The Office of Inspector General for the United States Health and Human Services Administration plans to evaluate the extent of pharmaceutical sales representative gift-giving in 2002, according to its recently released "Fiscal Year 2002 Work Plan."
The Office of Inspector General for the United States Health and Human Services Administration plans to evaluate the extent of pharmaceutical sales representative gift-giving in 2002, according to its recently released "Fiscal Year 2002 Work Plan."
In 1990, the Food and Drug Administration passed regulations prohibiting pharmaceutical companies from giving "gifts of substantial value" to physicians. According to the OIG, however, the pharmaceutical industry spends roughly $12 billion per year marketing pharmaceuticals to physicians. "Some of these gifts may present an inherent conflict of interest between the legitimate business goals of manufacturers and the ethical obligation of providers to prescribe drugs in the most rational way," read the 2002 plan. "Gifts may also violate the federal anti-kickback statute if they are intended to induce referrals."
Representative gift-giving has been coming under increased scrutiny lately. In August, the American Medical Association announced that it had created a working group to educate doctors on gift-giving guidelines and urge both physicians and pharmaceutical industry representatives to comply with them.
In addition to the gift-giving initiative, the Office of Inspector General is planning to review the effects of the Prescription Drug User Fee Act on "the regulatory review of new drug applications" and identify processes and programs that can improve the effectiveness and stringency of the review process. The OIG will also examine the FDA's practices regarding post-marketing studies of prescription drugs. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.